Penumbra Announces Partnership with RapidAI to Enable Faster Clinical Decision-Making for Pulmonary Embolism

Penumbra, Inc., a global healthcare company focused on innovative therapies, announced a new partnership to develop solutions to enable faster clinical decision-making for pulmonary embolism (PE) diagnosis and procedures with RapidAI, a company that offers a clinically proven, data-driven artificial intelligence (AI) platform that empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients.

“PE is at the precipice of a transformation in how patients affected by this condition are being treated. Several advances have been made during the last few years largely due to the PERT Consortium’s efforts, combined with innovation in therapeutic options,” said Robert Lookstein, MD MHCDL FSIR FAHA FSVM, president of the PERT Consortium, professor of Radiology and Surgery at Icahn School of Medicine at Mount Sinai (ISMMS) and executive vice chairman in The Department of Diagnostic, Molecular, and Interventional Radiology for the Mount Sinai Health System. “This exciting new partnership will undoubtedly help bring more awareness to this very deadly disease. The entire field wants to rapidly bring more therapeutic options to a broader segment of the population. We collectively believe this will only improve outcomes.”

Recommended AI News: American Crane Provides Industry Insight on New Education Initiative NYOUGENE From Youtopian

Penumbra and RapidAI will work together to develop several clinical and communications modules for pulmonary embolism, which is a deadly condition involving blood clots in the lungs. The modules are aimed to streamline triage and decision-making by processing CT scans and delivering clear, easy-to-interpret CT images directly to the physician. In addition, this partnership comes at a very important time, as the medical community is dealing with the COVID-19 pandemic where patient triage and remote access have become critical to the healthcare system.

“COVID-19 has heightened the need for AI technology that powers physicians’ ability to be connected to their healthcare institutions and care teams from remote locations and to speed up patient care,” said Don Listwin, chief executive officer, Rapid AI. “We are thrilled to be partnering with one of the most innovative medical device companies, Penumbra, to advance the field of PE by rising to these challenges with our powerful AI solutions.”

Recommended AI News: CoSoSys Adds New Key Features for Enterprises in Endpoint Protector 5.2.0.9

This new partnership with RapidAI demonstrates Penumbra’s continued commitment to advancing solutions for pulmonary embolism and follows the recent launch of the Indigo System with Lightning Intelligent Aspiration, Penumbra’s newest generation technology for the removal of blood clots in the arteries and veins and for the treatment of pulmonary embolism.

“Penumbra has been at the forefront of technology to address unmet clinical needs – be it in stroke, virtual rehab, intelligent aspiration and now pulmonary embolism,” said Adam Elsesser, chairman and chief executive officer, Penumbra Inc. “This partnership with RapidAI is another example of Penumbra’s commitment to provide cutting-edge solutions that help address the challenges faced by the medical community. We look forward to taking on this next frontier in the field of PE.”

Recommended AI News: DoiT International Appoints John Purcell as Chief Product Officer